Fore Pharma, Aug 2011, Pages: 13
Fore Pharma's latest report ‘Global BladderCancerDrug Pipeline Capsule – 2011' is an outline of all the key research and development (R&D) activities of the global bladdercancerdrug
Fore Pharma, Jan 2012, Pages: 13
Fore Pharma’s latest report ‘Global BladderCancerDrug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global bladdercancerdrug
Global Industry Analysts, Inc., Oct 2010, Pages: 580
Number of Drugs by
Development Stage (includes corresponding Graph/Chart) II-7
Emerging Therapeutic Options for Superficial BladderCancer II-8
Table 7: EOquin
GlobalData, April 2011, Pages: 308
Assessment
6.2.1 Technology Trends Analytic Framework
6.3 BladderCancer Therapeutics – Promising Drugs Under Clinical Development
6.4 Molecule Profile for Promising Drugs under Clinical Development
6
Jain PharmaBiotech, Feb 2012, Pages: 639
. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.
Drug delivery strategies vary according to the type and location of cancer. Role
Frost & Sullivan, Aug 2007, Pages: 94
. Moreover, no new drugs for bladdercancer have entered the market in two decades, which encourages the scope for novel treatments in the market.
Emerging treatment options include new cytotoxic drugs, new
Jain PharmaBiotech, Feb 2012, Pages: 281
for developing markets for transdermal drug delivery
- A selected bibliography of 200 publications
- Text is supplemented by 18 tables and 10 figures
Who should read this report?
- Biotechnology companies
Jain PharmaBiotech, Feb 2012, Pages: 864
and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only
Bioseeker, Oct 2010, Pages: 659
for the Treatment of BladderCancer
Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer
Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs
Bioseeker, Nov 2010, Pages: 777
Vaccine Drugs for the Treatment of B-cell Lymphoma
Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of BladderCancer
Table 60: Target Strategy Development Profiles
Life Science Analytics, March 2011, Pages: 192
BladderCancer Therapy Area Pipeline Report contains detailed information on the bladdercancerdrug pipeline. This report provides insight into the pipeline status of bladdercancerdrugs
GBI Research, Feb 2011, Pages: 209
Area, Global, Early Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December 2010
Table 19: Drug Discovery and Preclinical Molecules by Therapy Area, BladderCancer Therapeutics
Global Industry Analysts, Inc., Oct 2011, Pages: 897
corresponding
Graph/Chart) 56
Non-Hodgkin's Lymphoma 57
Leukemia 57
BladderCancer 57
Table 18: BladderCancerDrug Pipeline: Number of Drugs by
Development Stage as of 2010 (includes corresponding
Graph
Bioseeker, Feb 2011
rate is 94%.
There are today 93 (81) companies plus partners developing 104 (86) drugs targeting bladdercancer in development. In addition, there are 2 (4) suspended drugs and the accumulated number
Expert Reviews Ltd, June 2011, Pages: 210
as treatment for muscle-invasive bladdercancer
Michael A Morse, et al
PERSPECTIVE
- From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer
Ravi A Madan, et
Global Markets Direct, Dec 2010, Pages: 114
provides information on the therapeutic development for BladderCancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved
Informa Healthcare, Sep 2008, Pages: 256
Bladdercancer is an international public health problem affecting millions of people in both developed and underdeveloped nations. This major urologic malignancy was one of the first cancers
